Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL)

被引：0
|
作者：
Welt, A [1 ]
Fossa, A [1 ]
Blatter, J [1 ]
Buksmaui, S [1 ]
Seeber, S [1 ]
Nowrousian, MR [1 ]
机构：
[1] Univ Essen, Lilly Deutschland, W German Canc Ctr, Dept Med Oncol Canc Res, Bad Homburg, Germany
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
643
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [31] EFFICACY OF GEMCITABINE AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY AGGRESSIVE NON HODGKIN LYMPHOMA PATIENTS
    Zlotnick, M.
    Avigdor, A.
    Ribakovsky, E.
    Nagler, A.
    Kedmi, M.
    HAEMATOLOGICA, 2016, 101 : 696 - 696
  • [32] FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
    Child, JA
    Johnson, SA
    Rule, S
    Smith, GM
    Morgan, GJ
    Johnson, PWM
    Prentice, AG
    Tollerfield, SM
    Wareham, E
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 309 - 317
  • [33] International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma
    Czuczman, M. S.
    Reeder, C. B.
    Polikoff, J.
    Chowhan, N. M.
    Esseessee, I.
    Greenberg, R.
    Ervin-Haynes, A.
    Pietronigro, D.
    Zeldis, J. B.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Schade, Jake R.
    Kim, Charles
    Drill, Esther
    Qiu, Annie
    Batlevi, Connie Lee
    Caron, Philip
    Colbourn, Donald Steven
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Joffe, Erel
    von Keudell, Gottfried R.
    Kumar, Anita
    Noy, Ariela
    Okwali, Michelle
    Owens, Colette
    Palomba, M. Lia
    Rodriguez-Rivera, Ildefonso
    Sauter, Craig S.
    Schoder, Heiko
    Straus, David J.
    Vardhana, Santosha
    Younes, Anas
    Zelenetz, Andrew D.
    Matasar, Matthew J.
    BLOOD, 2019, 134
  • [35] Primary refractory disease in non-Hodgkin lymphoma (NHL)
    d'Amore, F.
    Brown, P.
    Pedersen, L. M.
    Pulczynski, B. B.
    Pedersen, M.
    Gadeberg, O.
    Bukh, A.
    Hansen, M.
    Pulczynski, S.
    Ingeberg, S.
    Andersen, T. M.
    Frederiksen, M.
    Moeller, M. B.
    Mortensen, L. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 132 - 132
  • [36] Intensification of salvage treatment with dice dose sequential chemotherapy (HDS) improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin lymphoma (NHL).
    Cortelazzo, S
    Rambaldi, A
    Rossi, A
    Oldani, E
    Lussana, F
    Ghielmini, M
    Benedetti, F
    Cantini, M
    Tarella, C
    Zallio, F
    Vitolo, U
    Di Nicola, M
    Pogliani, E
    Cavalli, F
    Barbui, T
    BLOOD, 2000, 96 (11) : 794A - 794A
  • [37] Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Santoro, A.
    Voglova, J.
    Gabrail, N.
    Ciuleanu, T.
    Liberati, M.
    Hancock, B. W.
    Stromatt, S.
    Caballero, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 441S - 441S
  • [38] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [39] Gemncitabine as a single agent in the treatment of relapsed or refractory Hodgkin's and non Hodgkin's lymphoma.
    Jajeh, A
    Hadad, L
    Zalzaleh, G
    Abboud, W
    Nukala, S
    BLOOD, 2002, 100 (11) : 299B - 299B
  • [40] Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma
    中华医学杂志(英文版), 2010, (22) : 3206 - 3211
12345